Calcium-channel blockers in ischemic heart disease

Current Opinion in Cardiology

Volumn 11, Issue 4, 1996, Pages 434-439

  Silvestry, Frank E ^a   Kimmel, Stephen E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ISRADIPINE; NIFEDIPINE; VERAPAMIL;

ACUTE HEART INFARCTION; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; DRUG USE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PHARMACEUTICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; UNSTABLE ANGINA PECTORIS;

ANGINA PECTORIS; ANGINA PECTORIS, VARIANT; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0029855630     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199607000-00013     Document Type: Review

References (45)

1. Horton R: Spinning the risks and benefits of calcium antagonists. Lancet 1995, 346:586-587. Editorial summarizing the current controversy and handling of the debate by the medical community.
2. Epstein M: Calcium antagonists in the management of hypertension. In Calcium Antagonists in Clinical Medicine. Edited by Epstein M. Philadelphia: Hanley and Belfus; 1995:213-230.
3. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB: Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995, 155:829-837.
4. Herbert PR, Fiebach NH, Eberlein KA, et al.: The community-based randomized trials of pharmacologic treatment of mild-to-moderate hypertension. Am J Epidemiol 1988, 127:581-590.
5. McClellan K: Unexpected results from MIDAS in atherosclerosis [abstract]. Inpharma 1994, 932:4.
6. Ferguson JJ, Monomura S: Highlights from the 58th Annual Scientific Meeting of the Japanese Circulation Society. Circulation 1994, 90:2194-2196.
7. Psaty BM, Heckbert SR, Koespell TD, Koespell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, et al.: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995, 274:620-625. In this retrospective, population-based, case-control study, prior pharmacotherapy for hypertension and risk of MI in patients on calcium antagonists is compared with a reference group of patients receiving diuretics. Found that overall risk of MI was increased 62% (OR, 1.62; 95% CI, 1.11 to 2.34; P = 0.01) among hypertensive patients without a history of coronary disease taking a calcium antagonist compared with those taking diuretics. MI risk in those treated with calcium antagonists was 57% higher (adjusted OR, 1.57; 95% CI, 1.21 to 2.04; P < 0.001) as compared with those treated with β-blockers.
8. Yusuf S, Held P, Furberg C: Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991, 67:1295-1297.
9. Hansen JF: Postinfarct treatment with verapamil. Drugs 1993, 46(suppl 2):54-60.
10. Rehnquist N, Hjendahl P, Billing E, Bjorkardur I, Eriksson SV, Forslund L, Held C, Nasman P, Wallen NH: Effects of metoprolol versus verapamil in patients with stable angina pectoris: the Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996, 17:76-78.
11. Strom BR: Bias and confounding in pharmacoepidemiology. In Pharmacoepidemiology, edn 2. Edited by Strom BR. New York: John Wiley and Sons; 1994:619-621.
12. Morris AD, Meredith PA, Reid JL: Pharmacokinetics of calcium antagonists: implications for therapy. In Calcium Antagonists in Clinical Medicine. Edited by Epstein M. Philadelphia: Hanley and Belfus; 1995:49-67.
13. Triggle DJ: Biochemical and pharmacologic differences among calcium channel antagonists: clinical implications. In Calcium Antagonists in Clinical Medicine. Edited by Epstein M. Philadelphia: Hanley and Belfus; 1995:1-27.
14. Ruzicka M, Leenen FHH: Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In Hypertension: Pathophysiology, Diagnosis, and Management, edn 2. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2815-2825.
15. Epstein M: Calcium antagonists should continue to be used for first line treatment of hypertension. Arch Intern Med 1995, 155:2150-2156. Review summarizing important pharmacologic and physiologic differences between calcium antagonists, as well reviewing current human studies on calcium antagonists and atherosclerosis.
16. Pahor M, Guralnik JM, Corti M-C, Foley DJ, Carbonin P, Havlik RJ: Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995, 43:1191-1197. This prospective cohort study among hypertensive geriatric patients comparing mortality associated with antihypertensive therapy using short-acting calcium channel antagonists and ACE inhibitors with β-blockers found that relative risk of mortality was 0.8 (95% CI, 0.4 to 1.4) tor verapamil, 1.3 (95% CI, 0.8 to 2.1) for diltiazem, 1.7 (95% CI, 1.1 to 2.7) for nifedipine, and 0.9 (95% CI, 0.6 to 1.4) for ACE inhibitors.
17. Antman E, Muller J, Goldberg S, MacAlpin R, Rubenfire M, Tabatznik B, Liang C-S, Heupler F, Achuff S, Reichek N, et al.: Nifedipine therapy for coronary artery spasm: experience in 127 patients. N Engl J Med 1980, 302:1269-1273.
18. Taylor SH: Usefulness of amlodipine for angina pectoris. Am J Cardiol 1994, 73:28A-33A.
19. Stone PH, Antman EM, Muller JE, Braunwald E: Calcium Channel blocking agents in the treatment of cardiovascular disorders: part II. Hemodynamic effects and clinical applications. Ann Intern Med 1980, 93:336-904.
20. Cohn PF, Vetrovec GW, Nesto R, and the Total Ischemia Awareness Program Investigators: The Nifedipine-Total Ischemia Awareness Program: a national survey of painful and painless myocardial ischemia including results of anti-ischemic therapy. Am J Cardiol 1989, 63:534-539.
21. Rice KR, Gervino E, Jarisch WR, Stone PH: Effects of nifedipine on myocardial perfusion during exercise in chronic stable angina. Am J Cardiol 1990, 65:1097-1101.
22. Rouseau MF, Vincent MF, Van Hoof F, Berghe GVD, Charlier AA, Pouler H: Effects of nicardipine and nisoldipine on myocardial metabolism, coronary blood flow and oxygen supply in angina pectoris. Am J Cardiol 1984, 54:1189-1194.
23. Glasser SP, Clark PI, Lipicky RJ, Hubbard JM, Yusuf S: Exposing patients with chronic, stable angina to placebo periods in drug trials. JAMA 1991, 265:1550-1554.
24. Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, Roberts R, Pearle DL, Turi ZG, Schneider JF, Serfas DH, et al.: Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 1984, 69:740-747.
25. Gerstenblith G, Ouyang P, Achuff SC, Bulkley BH, Becker LC, Mellits ED, Baughman KL, Weiss JL, Flahery JT, Kallman CH, et al.: Nifedipine in unstable angina: a double-blind, randomized trial. N Engl J Med 1982, 306:885-889.
26. Muller JE, Turi ZG, Pearle DL, Schneider JF, Serfas DH, Morrison J, Stone PH, Rude RE, Rosner B, Sobel BE, et al.: Nifedipine and conventional therapy for unstable angina pectoris: a randomized, double-blind comparison. Circulation 1984, 69:728-739.
27. Furberg CD, Psaty BM, Meyer JV: Nifedipine: dose related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1326-1331. This meta-analysis of 14 prior studies examining the effect of acute-release nifedipine dose on mortality rates in patients with symptomatic coronary artery disease demonstrated a significant dose-response effect of nifedipine on the risk of mortality. The risk ratio for specific doses of nifedipine was statistically significant only in studies using doses of greater than 80 mg/d (risk ratio, 2.83; 95% CI, 1.35 to 5.93). The overall risk ratio was 1.16 (95% CI, 1.01 to 1.33) for patients taking any dose of nifedipine.
28. Kloner RA: Nifedipine in ischemic heart disease. Circulation 1995, 92:1074-1078. Review that summarizes limitations of Furberg et al.'s (Circulation 1995, 92:1326-1331) meta-analysis, and reviews available data on longer-acting calcium antagonists.
29. Lichtlen PR, Hugenhoitz PG, Rafflenbeul W, Hecket H, Jost S, Deckers JW: Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990, 335:1109-1113.
30. Messerli FH: Are calcium antagonists safe? [Letter]. Lancet 1995, 346:767-768.
31. Messerli FH, Opie LH, Chambers R: Long-term safety of calcium antagonists: reassesment of the Furberg hypothesis [abstract]. J Am Coll Cardiol 1996, 27(suppl):319A. Recalculates Furberg et al.'s (Circulation 1995, 92:1326-1331) meta-analysis excluding INTACT, finding less significant overall association (P = 0.36) of calcium antagonists with increased mortality.
32. Opie LH, Messerli FH: Nifedipine and mortality: grave defects in the dossier. Circulation 1995, 92:1068-1073. Reviews potential limitations with Furberg et al.'s (Circulation 1995, 92:1326-1331) meta-analysis, and possible mechanisms of adverse events. Reanalyzes Furberg's meta-analysis and also includes 6-month mortality data from Muller et al.'s (Circulation 1984, 689:740-747) study, finding less significant overall associations (P = 0.046 and P = 0.13, respectively).
33. Rengo F, Carbonin P, Pahor M, De Caprio L, Bernabei R, Ferrara N, Carosella L, Acanfora D, Parlati S, Vitale D, and the CRIS Investigators: A controlled trial of verapamil in patients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Study (CRIS). Am J Cardiol 1996, 77:366-369. Multicenter, double-blind, randomized, placebo-controlled trial of verapamil in patients after acute MI not receiving β-blockers. During a mean follow-up period of 23.5 months, there was no difference in total mortality with verapamil and placebo (n = 30 and n = 29, respectively), and cardiac death (n = 21 vs n = 22). A nonsignificant trend toward lower nonfatal reinfarction rates was found (n = 39 vs n = 49).
34. Yusuf S: Verapamil following uncomplicated myocardial infarction: promising, but not proven. Am J Cardiol 1996, 77:421-422. Combines new data from CRIS with older data from DAVIT-I and -II. Patients treated with verapamil compared with placebo had lower mortality and reinfarction rates (15.1% vs 17.2%; OR, 0.86; 95% CI, 0.73 to 1.01). Verapamil is likely safe and may reduce reinfarction in patients with good ventricular function.
35. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE, et al., and the Diltiazem Reinfarction Study Group: Diltiazem and reinfarction in patients with non-Q wave myocardial infarction: results of a double-blind randomized, multicenter trial. N Engl J Med 1986, 315:423-429.
36. Kjekshus JK: Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986, 57:43F-49F.
37. The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988, 319:385-392.
38. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S: Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991, 83:52-60.
39. The Danish Study Group on Verapamil in Myocardial Infarction: The Danish studies on verapamil in acute myocardial infarction. Br J Clin Pharmacol 1986, 21:197S-204S.
40. Ljung B: Vascular selectivity of felodipine. Drugs 1985, 29(suppl):46-58.
41. Redfield MM, Neumann A, Tajik AJ, Seward JB, Borrow KM: Effect of long acting felodipine and nifedipine on left ventricular contractility in patients with systemic hypertension: differentiating between reflex sympathetic and contractile responses [abstract]. J Am Coll Cardiol 1994, Special Issue:348A.
42. Cohn JN, Ziesche SM, Loss LE, Anderson GF, and the V-HeFT Study Group: Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT III [abstract]. Circulation 1995, 92(suppl):I-143.
43. Neergaard L: Most hypertension drugs deemed safe by scientific panel. New York: Associated Press; January 26, 1996.
44. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The Fifth report of the Joint National Committee (JNC V). Arch Intern Med 1993, 153:713-724.
45. Yusuf S: Calcium antagonists in coronary artery disease and hypertension: time for reevaluation. Circulation 1995, 92:1079-1082. Reviews prior studies on calcium-channel blockers in hypertension and coronary artery disease. Summarizes ongoing randomized clinical trials of calcium antagonists in cardiovascular disease.